BeyondSpring Inc. (BYSI): R&D Expense
$4.39M
Year ended 2025-12-31
$4.56M
Trailing 12 months to 2026-06-30
-44.4%
3-year compound annual growth
-36.3%
5-year compound annual growth
-3.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.39M | +66.0% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $2.64M | -63.6% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $7.27M | -71.6% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $25.58M | -30.6% | 2023-04-18, From 2022-01-01 |
| 2021-12-31 | $36.89M | -11.7% | 2023-04-18, From 2021-01-01 |
| 2020-12-31 | $41.79M | +33.3% | 2023-04-18, From 2020-01-01 |
| 2019-12-31 | $31.34M | -39.3% | 2022-04-14, From 2019-01-01 |
| 2018-12-31 | $51.62M | -42.0% | 2021-04-30, From 2018-01-01 |
| 2017-12-31 | $88.93M | +752.0% | 2020-04-30, From 2017-01-01 |
| 2016-12-31 | $10.44M | +66.1% | 2019-04-30, From 2016-01-01 |
| 2015-12-31 | $6.28M | +234.9% | 2018-04-03, From 2015-01-01 |
| 2014-12-31 | $1.88M | n/a | 2017-04-28, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $4.39M | +66.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare BYSI, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗